Nasdaq: $29.27 (+0.03) | AIM: £4.18 (-0.01)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Mailing List Sign-up
Shareholder Information
Overview
Events, Circulars & Forms
Major Shareholders
Financial Reports
SEC Filings
Share Price & Chart
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
Careers
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Mailing List Sign-up
Shareholder Information
Overview
Events, Circulars & Forms
Major Shareholders
Financial Reports
SEC Filings
Share Price & Chart
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
Audit Committee – Terms of Reference
AIM Rule 26
Careers
News & Presentations
Hutchmed
| News & Presentations
Key RNS & Press Releases
8 Apr 2021
HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia
Read more
29 Mar 2021
HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies
Read more
26 Mar 2021
2020 Annual Report and Notice of Annual General Meeting
Read more
24 Mar 2021
HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million
Read more
Presentations & Publications
7 Apr 2021
Corporate Presentation
Read more
4 Mar 2021
2020 Full Year Financial Results
Read more
15 Jan 2021
ASCO-GI 2021: FRESCO-2 global Phase III study of fruquintinib in mCRC
Read more
5 Dec 2020
ASH2020: Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral PI3Kδ Inhibitor, in Chinese Patients with Relapsed/Refractory Lymphomas
Read more
Other UK Regulatory Notices
29 Mar 2021
Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme
Read more
10 Mar 2021
Vesting of awards under the Long Term Incentive Plan
Read more
3 Feb 2021
Chi-Med to Announce 2020 Final Results
Read more
31 Dec 2020
Blocklisting Six Monthly Return
Read more
31 Dec 2020
Total Voting Rights
Read more
15 Dec 2020
Grant of Share Options under Share Option Scheme
Read more
Mailing List Sign-up
If you would like to be kept up to date with the latest news of HUTCHMED, please sign up to our mailing list . We will deliver the relevant material directly to your email box as soon as it becomes available online.